Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...
Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...
Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based ...
Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.
UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...
Cipla partners with ImmunoAct to introduce India’s first CAR-T cell therapy in Africa, enhancing accessible cancer treatment ...
Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Under healthy conditions, the intestinal epithelium fully renews itself every three to five days. Aging and exposure to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results